GTS Securities’s Standard BioTools LAB Stock Holding History

GTS Securities’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,538	Closed	-$26.7K	–	1629
2025 Q3	$26.7K	Buy	+20,538	New	+$26.9K	﹤0.01%	1383

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

GTS Securities's LAB Position: Q4 2025 in Review

GTS Securities sold out of Standard BioTools (LAB) in Q4 2025, closing a stake of 20,538 shares — an estimated $26.7K sold.

GTS Securities first reported a position in LAB in Q3 2025 and held it in 1 quarter. The position peaked at $26.7K in Q3 2025. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

GTS Securities reported no remaining Standard BioTools position as of Q4 2025 after selling out during the quarter.
GTS Securities sold 20,538 Standard BioTools shares in Q4 2025, an estimated $26.7K.
GTS Securities first reported a position in Standard BioTools in Q3 2025 and held it in 1 quarter.
GTS Securities's Standard BioTools position peaked at $26.7K in Q3 2025.
159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on GTS Securities's 13F filing for Q4 2025, filed 13 Feb 2026.